CLDX FY 2019 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-62.5% YoY

Gross Profit

-$39M-1094.3% margin

Operating Income

-$55M-1540.2% margin

Net Income

-$51M-1424.0% margin

EPS (Diluted)

$-3.51

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$123M

Total Liabilities

$29M

Stockholders' Equity

$94M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$10M	-62.5%
Gross Profit	-$39M	-$57M	+31.3%
Operating Income	-$55M	-$156M	+64.8%
Net Income	-$51M	-$151M	+66.3%